Leukemia, Myeloid, Chronic-Phase
"Leukemia, Myeloid, Chronic-Phase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The initial phase of chronic myeloid leukemia consisting of an relatively indolent period lasting from 4 to 7 years. Patients range from asymptomatic to those exhibiting ANEMIA; SPLENOMEGALY; and increased cell turnover. There are 5% or fewer blast cells in the blood and bone marrow in this phase.
MeSH Number(s)
C04.557.337.539.250.400
C15.378.190.636.370.400
Concept/Terms
Leukemia, Myeloid, Chronic-Phase- Leukemia, Myeloid, Chronic-Phase
- Granulocytic Leukemia, Chronic, Stable-Phase
- Leukemia, Granulocytic, Chronic Phase
- Leukemia, Granulocytic, Chronic-Phase
- Leukemia, Myelogenous, Chronic Phase
- Leukemia, Myelogenous, Chronic-Phase
- Leukemia, Myeloid, Chronic Phase
- Leukemia, Myeloid, Stable Phase
- Leukemia, Myeloid, Stable-Phase
- Myelogenous Leukemia, Chronic, Chronic Phase
- Myelogenous Leukemia, Chronic, Chronic-Phase
- Myeloid Leukemia, Chronic, Chronic Phase
- Myeloid Leukemia, Chronic, Chronic-Phase
- Myeloid Leukemia, Chronic, Stable-Phase
- Granulocytic Leukemia, Chronic, Stable Phase
Below are MeSH descriptors whose meaning is more general than "Leukemia, Myeloid, Chronic-Phase".
- Diseases [C]
- Neoplasms [C04]
- Neoplasms by Histologic Type [C04.557]
- Leukemia [C04.557.337]
- Leukemia, Myeloid [C04.557.337.539]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C04.557.337.539.250]
- Leukemia, Myeloid, Chronic-Phase [C04.557.337.539.250.400]
- Hemic and Lymphatic Diseases [C15]
- Hematologic Diseases [C15.378]
- Bone Marrow Diseases [C15.378.190]
- Myeloproliferative Disorders [C15.378.190.636]
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive [C15.378.190.636.370]
- Leukemia, Myeloid, Chronic-Phase [C15.378.190.636.370.400]
Below are MeSH descriptors whose meaning is more specific than "Leukemia, Myeloid, Chronic-Phase".
This graph shows the total number of publications written about "Leukemia, Myeloid, Chronic-Phase" by people in Harvard Catalyst Profiles by year, and whether "Leukemia, Myeloid, Chronic-Phase" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 3 | 0 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 3 | 0 | 3 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 0 | 1 |
Below are the most recent publications written about "Leukemia, Myeloid, Chronic-Phase" by people in Profiles.
-
Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia. Am J Hematol. 2022 Nov; 97(11):1419-1426.
-
Low-dose dasatinib: when less can be more. Lancet Haematol. 2021 12; 8(12):e867-e868.
-
Future Directions in Chronic Phase CML Treatment. Curr Hematol Malig Rep. 2021 12; 16(6):500-508.
-
BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase. Br J Haematol. 2022 01; 196(1):136-145.
-
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 10 01; 18(10):1385-1415.
-
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. Leuk Lymphoma. 2020 12; 61(12):2811-2820.
-
T315I mutation with lymphoblasts in a newly diagnosed patient with chronic-phase chronic myeloid leukemia. Leuk Lymphoma. 2019 06; 60(6):1591-1594.
-
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2016 12; 14(12):1505-1512.
-
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia. Clin Lymphoma Myeloma Leuk. 2016 06; 16(6):341-349.e1.
-
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases. Blood. 2016 04 28; 127(17):2131-43.